After enrolling in SAFIR02 (ClinicalTrials.gov identifier: NCT02299999), targeted panel sequencing (Ion Torrent PGM; Thermo Fisher Scientific, Villebon, France) of a fresh tumor biopsy sample revealed the presence of a heterozygous germline PTEN mutation (c.389G>A, p.R130Q, SNP rs121909229) alongside other variants (Fig 1A; Data Supplement). This evidence concerns the gene PTEN and neoplasm.